EGFR and cancer: Interestingly, gDNA did not show KRAS mutations in either CTC subpopulation in all cases, which can be an opportunity for combinational therapies that include anti-EGFR monoclonal antibodies, since wild-type KRAS cancer cells may be sensitive to these therapies [44,45].